SAB Biotherapeutics Gross Profit

The latest gross profit for SABS is $-1.5M as of June 2026. That compares with $5.8M in the prior-year period — down 126.4% year over year. That is below the sector sector average of $750M. Investors often review this figure alongside SAB Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SABS's gross profit moved from $5.8M to $-1.5M — a 126.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SAB Biotherapeutics's operating scale or balance-sheet position.

Against its sector companies, SABS currently prints $-1.5M for gross profit, while the sector average sits near $750M. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at SAB Biotherapeutics's growth, margins, and balance sheet.

A gross profit figure of $-1.5M for SABS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $750M. Explore the charts below for those layers of context.

After noting SABS's gross profit ($-1.5M), review year-over-year change from $5.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.